Literature DB >> 16121982

Embryonic stem cell-derived astrocytes expressing drug-inducible transgenes: differentiation and transplantion into the mouse brain.

Ronald J Benveniste1, Gordon Keller, Isabelle Germano.   

Abstract

OBJECT: Embryonic stem cell (ESC)-derived astrocytes have many theoretical and practical advantages as vectors for delivery of gene therapy to the central nervous system (CNS). The aim of this study was to generate highly pure populations of ESC-derived astrocytes expressing drug-inducible transgenes, while minimizing contamination by undifferentiated ESCs
METHODS: Embryonic stem cells carrying a doxycycline-inducible green fluorescent protein (GFP) transgene were induced to differentiate into astrocytes by using feeder cell-free conditions that are completely defined. More than 95% of these cells expressed the astrocyte markers glial fibrillary acidic protein and GLT-1 glutamate transporter, and the morphological characteristics of these cells were typical of astrocytes. The expression of additional astrocyte markers was detected using reverse transcription-polymerase chain reaction. Undifferentiated ESCs comprised fewer than 0.1% of the cells after 10 days in this culture. Positive and negative selection techniques based on fluorescence-activated cell sorting were successfully used to decrease further the numbers of undifferentiated ESCs. Fully differentiated astrocytes expressed a GFP transgene under the tight control of a doxycycline-responsive promoter, and maintained their astrocytic phenotype 24 hours after transplantation into the mouse brain.
CONCLUSIONS: This study shows that transgenic ESCs can be induced to differentiate into highly pure populations of astrocytes. The astrocytes continue to express the transgene under the tight control of a drug-inducible promoter and are suitable for transplantation into the mouse brain. The number of potentially hazardous ESCs can be minimized using cell-sorting techniques. This strategy may be used to generate cellular vectors for delivering gene therapy to the CNS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16121982     DOI: 10.3171/jns.2005.103.1.0115

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

Review 2.  Finding degrees of separation: experimental approaches for astroglial and oligodendroglial cell isolation and genetic targeting.

Authors:  Li-Jin Chew; Cynthia A DeBoy; Vladimir V Senatorov
Journal:  J Neurosci Methods       Date:  2014-08-26       Impact factor: 2.390

3.  Different Mixed Astrocyte Populations Derived from Embryonic Stem Cells Have Variable Neuronal Growth Support Capacities.

Authors:  Russell E Thompson; Allison Lake; Peter Kenny; Michael N Saunders; Kristina Sakers; Nisha R Iyer; Joseph D Dougherty; Shelly E Sakiyama-Elbert
Journal:  Stem Cells Dev       Date:  2017-10-17       Impact factor: 3.272

Review 4.  Stem cells for spinal cord injury: Strategies to inform differentiation and transplantation.

Authors:  Nisha R Iyer; Thomas S Wilems; Shelly E Sakiyama-Elbert
Journal:  Biotechnol Bioeng       Date:  2016-09-21       Impact factor: 4.530

Review 5.  Derivation of Specific Neural Populations From Pluripotent Cells for Understanding and Treatment of Spinal Cord Injury.

Authors:  Nicholas White; Shelly E Sakiyama-Elbert
Journal:  Dev Dyn       Date:  2018-11-26       Impact factor: 3.780

6.  In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas.

Authors:  Mahmud Uzzaman; Gordon Keller; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

Review 7.  Stem cells and gliomas: past, present, and future.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

Review 8.  Glia-neuron interactions in neurological diseases: Testing non-cell autonomy in a dish.

Authors:  Kathrin Meyer; Brian K Kaspar
Journal:  Brain Res       Date:  2016-01-09       Impact factor: 3.252

Review 9.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  "Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy.

Authors:  Elisabetta Mormone; Sunita D'Sousa; Vera Alexeeva; Maria M Bederson; Isabelle M Germano
Journal:  Stem Cells Dev       Date:  2014-07-25       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.